Anzeige
Mehr »
Montag, 18.05.2026 - Börsentäglich über 12.000 News
Während viele nur über AI sprechen, baut dieses Unternehmen bereits die Infrastruktur dafür
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMBD | ISIN: CA52731E1060 | Ticker-Symbol: 75J
Frankfurt
07.05.26 | 09:10
0,025 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEVELJUMP HEALTHCARE CORP Chart 1 Jahr
5-Tage-Chart
LEVELJUMP HEALTHCARE CORP 5-Tage-Chart

Aktueller Chart LEVELJUMP HEALTHCARE Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
LEVELJUMP HEALTHCARE CORP-Investoren interessieren sich auch für diese Wertpapiere
Noble Financial Group, Inc.: P3 Health Partners to Present at the Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceHenderson, Nevada--(Newsfile Corp. - November 24, 2025) - P3 Health Partners Inc. (NASDAQ: PIII) ("P3"), a patient-centered and physician-led population health management company, today announced that...
► Artikel lesen
Heartflow, Inc.: Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 GuidanceSAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the...
► Artikel lesen
Heartflow, Inc.: Heartflow Files Patent Infringement Lawsuit Against CleerlyMOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed...
► Artikel lesen
Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery DiseaseLesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN...
► Artikel lesen
BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue GuidanceMENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that...
► Artikel lesen
BillionToOne, Inc.: BillionToOne Provides Guidance for 2026MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
► Artikel lesen
BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 ResultsMENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
► Artikel lesen